Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 3, Pages 639
Publisher
MDPI AG
Online
2020-03-12
DOI
10.3390/cancers12030639
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management
- (2019) Geoffrey Boulate et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Prolonged Adrenal Insufficiency After Discontinuation Of Mitotane Therapy
- (2019) Leonardo Muratori et al. Endocrine Metabolic & Immune Disorders-Drug Targets
- The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
- (2019) P M van Koetsveld et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A simplified method for therapeutic drug monitoring of mitotane by gas chromatography‐electron ionization‐mass spectrometry
- (2019) Motozumi Ando et al. BIOMEDICAL CHROMATOGRAPHY
- European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
- (2018) Martin Fassnacht et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effects of mitotane on the hypothalamic–pituitary–adrenal axis in patients with adrenocortical carcinoma
- (2017) Giuseppe Reimondo et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma
- (2017) Alfredo Berruti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma
- (2017) Jessica Cusato et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- The Lack of Antitumor Effects of o,p′DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment
- (2014) Ségolène Hescot et al. Hormones & Cancer
- Adjuvant Therapies and Patient and Tumor Characteristics Associated With Survival of Adult Patients With Adrenocortical Carcinoma
- (2013) Tobias Else et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of mitotane treatment on human steroid metabolism: implications for patient management
- (2012) L Ghataore et al. Endocrine Connections
- Plasma Concentrations of o,p′DDD, o,p′DDA, and o,p′DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study
- (2011) Ilse G. Hermsen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
- (2010) Martin Fassnacht et al. CLINICAL ENDOCRINOLOGY
- Improved Survival in Patients with Stage II Adrenocortical Carcinoma Followed Up Prospectively by Specialized Centers
- (2010) Martin Fassnacht et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Aktuelle TNM-Klassifikationssysteme für das Nebennierenkarzinom
- (2010) M. Fassnacht et al. PATHOLOGE
- Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly
- (2008) F. Daffara et al. ENDOCRINE-RELATED CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More